Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 9408965

Complement and complement deficiencies.

K Whaley·W Schwaeble
View original source ↗Export metadata ↓

Abstract

The complement system provides a first line of defense and mediates a large variety of cellular and humoral interactions within the immune response, including chemotaxis, phagocytosis, cell adhesion, and B-cell differentiation. The system involves more than 30 serum components and numerous cell surface regulators and receptors. Similar to the blood clotting system, complement activation is initiated through a series of complex activation cascades involving enzymatic cleavage. Three independent complement activation cascades, the classical, the alternative, and the lectin pathway, have been described. The liver is the main site of biosynthesis for most of the serum components of complement and diseases of the liver can lead to alterations of the normally stable plasma levels of complement. Deficiencies of single components can lead to a broad variety of secondary diseases, caused by either imbalanced activation or defects in the humoral or cellular response to microbial infections.

Explore related subjects

Complement C3aComplement C3bComplement C5aComplement Pathway, ClassicalHumansImmune SystemImmunity, CellularReceptors, ComplementJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Whaley, W Schwaeble. 1997. Complement and complement deficiencies.. https://doi.org/10.1055/s-2007-1007206

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Increased amounts of C3a and the terminal complement complex at high dialysis blood-flow: the relation with dialysis efficiency.

To estimate the influence of blood-flow on complement generation and the relation with dialysis efficacy (KT/V) 10 patients underwent cuprophan hemodialyses for 6 h using low (200 ml/min) or high (400 ml/min) blood-flow (n = 40). Dialysis with high blood-flow compared to low induced a more rapid drop in leukocyte count and a more pronounced leukocyte rebound. Net generation of C3a (microgram/min) was also larger at all 15 measuring points during high blood-flow dialysis and there was significantly larger total generation of C3a (after 3 h p < 0.05, after 6 h p < 0.05) as compared to low blood-flow. Reaching a KT/V of 1.2-1.4 with high blood-flow induced a 40% larger total net generation of C3a and 21% more of TCC than with low blood-flow. Net generation of TCC (AU/min) was higher during the first and last parts of high blood-flow dialysis compared to low. In conclusion, increased blood-flow in order to increase dialysis efficiency (KT/V 1.2-1.4) results in larger net infusion of complement products with possible impact on immune response and complement-associated pathophysiological mechanisms.

Complement C3a↗
PubMed1996

Activation of circulating polymorphonuclear leukocytes in preterm infants with severe idiopathic respiratory distress syndrome.

We have studied activation of circulating polymorphonuclear leukocytes (PMN) in plasma of preterm infants with severe idiopathic respiratory distress syndrome (IRDS group, n = 15) and without IRDS (reference group, n = 15) during the first 5 postnatal days. We have observed lower median PMN counts in the IRDS group than in the reference group from d 2 (1.4 x 10(9)/L versus 4.8 x 10(9)/L in the reference group, p < 0.001) to d 4 to 6 (1.6 x 10(9)/L versus 4.0 x 10(9)/L, p < 0.01). Lower PMN counts in the IRDS infants were accompanied by lower median plasma elastase-alpha1-proteinase inhibitor (PI) concentrations (53.6 ng/mL versus 128.0 ng/mL in the reference group on d 2, p < 0.05). Simultaneously, median elastase-alpha1-PI/PMN ratios of these infants were significantly higher (40.8 ng/10(6) PMN versus 21.8 ng/10(6) PMN on d 2, p < 0.05), indicating activation of circulating PMN. Activation of circulating PMN in the IRDS group is associated with platelet-activating factor (PAF) release and complement activation from within 6 to 12 h of birth but not with release of tumor necrosis factor-alpha. PAF release was represented by significantly reduced inhibiting capacity (58% of normal human plasma, p < 0.01) and complement activation by higher median plasma C3a des-Arg concentrations (1680 ng/mL versus 325 ng/mL in the reference group, p < 0.001). We conclude that circulating PMN are activated in preterm infants with severe IRDS, which might be caused by systemic PAF release and complement activation. This activation process may play a role in the pathogenesis of the IRDS by influx of activated PMN into the lungs.

Complement C3a↗